Literature DB >> 19116979

Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.

Aimee O Hersh1, Emily von Scheven, Jinoos Yazdany, Pantelis Panopalis, Laura Trupin, Laura Julian, Patricia Katz, Lindsey A Criswell, Edward Yelin.   

Abstract

OBJECTIVE: To compare differences in long-term outcome between adults with childhood-onset (age at diagnosis <18 years) systemic lupus erythematosus (SLE) and with adult-onset SLE.
METHODS: Data were derived from the University of California Lupus Outcomes Study, a longitudinal cohort of 885 adult subjects with SLE (90 childhood-onset [cSLE], 795 adult-onset [aSLE]). Baseline and 1-year followup data were obtained via structured 1-hour telephone interviews conducted between 2002 and 2006. Using self-report data, differences in organ involvement and disease morbidity, current disease status and activity, past and current medication use, and number of physician visits were compared, based on age at diagnosis of SLE.
RESULTS: Average disease duration for the cSLE and aSLE subgroups was 16.5 and 13.4 years, respectively, and mean age at followup was 30.5 and 49.9 years, respectively. When compared with aSLE subjects, cSLE subjects had a higher frequency of SLE-related renal disease, whereas aSLE subjects were more likely to report a history of pulmonary disease. Rates of clotting disorders, seizures, and myocardial infarction were similar between the 2 groups. At followup, cSLE subjects had lower overall disease activity, but were more likely to be taking steroids and other immunosuppressive therapies. The total number of yearly physician visits was similar between the 2 groups, although cSLE subjects had a higher number of nephrology visits.
CONCLUSION: This study demonstrates important differences in the outcomes of patients with cSLE and aSLE, and provides important prognostic information about long-term SLE disease activity and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19116979      PMCID: PMC2875186          DOI: 10.1002/art.24091

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.

Authors:  Hermine I Brunner; Earl D Silverman; Theresa To; Claire Bombardier; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2002-02

2.  Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation.

Authors:  A J Swaak; H G van den Brink; R J Smeenk; K Manger; J R Kalden; S Tosi; A Marchesoni; Z Domljan; B Rozman; D Logar; G Pokorny; L Kovacs; A Kovacs; P G Vlachoyiannopoulos; H M Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; N Cikes; A Branimir; M Schneider; R Fischer; S Bombardieri; M Mosca; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  1999-10       Impact factor: 7.580

3.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

4.  Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus.

Authors:  Paivi M Miettunen; Oliva Ortiz-Alvarez; Ross E Petty; Rolando Cimaz; Peter N Malleson; David A Cabral; Stephanie Ensworth; Lori B Tucker
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

5.  Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study.

Authors:  Angelo Ravelli; Carolina Duarte-Salazar; Silvia Buratti; Andreas Reiff; Bram Bernstein; Maria Rocio Maldonado-Velazquez; Rosalia Beristain-Manterola; Nobuaki Maeno; Syuji Takei; Valeria Gerloni; Charles H Spencer; Polyxeni Pratsidou-Gertsi; Nicolino Ruperto; Angela Pistorio; Alberto Martini
Journal:  Arthritis Rheum       Date:  2003-08-15

6.  Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies.

Authors:  E W Karlson; L H Daltroy; C Rivest; R Ramsey-Goldman; E A Wright; A J Partridge; M H Liang; P R Fortin
Journal:  Lupus       Date:  2003       Impact factor: 2.911

7.  Analysis of clinical and laboratory profile in Indian childhood systemic lupus erythematosus and its comparison with SLE in adults.

Authors:  I Pande; N G Sekharan; S Kailash; S S Uppal; R R Singh; A Kumar; A N Malaviya
Journal:  Lupus       Date:  1993-04       Impact factor: 2.911

8.  Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII).

Authors:  L B Tucker; A G Uribe; M Fernández; L M Vilá; G McGwin; M Apte; B J Fessler; H M Bastian; J D Reveille; G S Alarcón
Journal:  Lupus       Date:  2008-04       Impact factor: 2.911

9.  Lupus nephritis: prognostic factors in children.

Authors:  D K McCurdy; T J Lehman; B Bernstein; V Hanson; K K King; R Nadorra; B H Landing
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

10.  Systemic lupus erythematosus in the younger patient: survival studies.

Authors:  M Abeles; J D Urman; A Weinstein; M Lowenstein; N F Rothfield
Journal:  J Rheumatol       Date:  1980 Jul-Aug       Impact factor: 4.666

View more
  57 in total

1.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  Psychotic Symptoms in a Child with Long Standing SLE Nephritis: Neuropsychiatric Manifestation or Sequelae to Lupus?

Authors:  Ananya Mahapatra; Pawan Sharma; Rajesh Sagar
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2016-05-01

3.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

4.  Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.

Authors:  Cécile Picard; Jean-Christophe Lega; Bruno Ranchin; Pierre Cochat; Natalia Cabrera; Nicole Fabien; Alexandre Belot
Journal:  Pediatr Nephrol       Date:  2017-03-25       Impact factor: 3.714

5.  Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort.

Authors:  Deborah M Levy; Christine A Peschken; Lori B Tucker; Gaëlle Chédeville; Adam M Huber; Janet E Pope; Earl D Silverman
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

Review 6.  Adult outcomes of childhood-onset rheumatic diseases.

Authors:  Aimee Hersh; Emily von Scheven; Ed Yelin
Journal:  Nat Rev Rheumatol       Date:  2011-04-12       Impact factor: 20.543

7.  Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample.

Authors:  Edward Yelin; Chris Tonner; Laura Trupin; Pantelis Panopalis; Jinoos Yazdany; Laura Julian; Patricia Katz; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2009-02-15

8.  Spectrum of systemic lupus erythematosus in Oman: from childhood to adulthood.

Authors:  Asma Al Rasbi; Eiman Abdalla; Rabab Sultan; Nasreen Abdullah; Juma Al Kaabi; Ibrahim Al-Zakwani; Reem Abdwani
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

Review 9.  [Transition from pediatric to adult rheumatological care].

Authors:  K Minden; S Schalm
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 10.  Cognitive and emotional abnormalities in systemic lupus erythematosus: evidence for amygdala dysfunction.

Authors:  Philip Watson; Justin Storbeck; Paul Mattis; Meggan Mackay
Journal:  Neuropsychol Rev       Date:  2012-08-11       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.